Latest Expert Opinions

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
December 19, 2018
It has always been too expensive for him. Maybe they have built out too many stores, but it has had a hard time continuing to justify valuations.
Starbucks(SBUX-Q)
December 19, 2018
It has always been too expensive for him. Maybe they have built out too many stores, but it has had a hard time continuing to justify valuations.
Gordon Reid
President, GoodReid Investment Counsel
Price
$64.060
Owned
No
HOLD
HOLD
December 19, 2018
Health insurer in the US. With Obama Care, it is hard to know if it will be repealed or not. A good company, trading at reasonable valuations.
Anthem Inc(ANTM-N)
December 19, 2018
Health insurer in the US. With Obama Care, it is hard to know if it will be repealed or not. A good company, trading at reasonable valuations.
Gordon Reid
President, GoodReid Investment Counsel
Price
$257.610
Owned
Yes
DON'T BUY
DON'T BUY
December 19, 2018
They try to manage their P&L well to earn a 7-9% earnings growth rate and the yields have competed well against bonds. He is hesitant on this space, because society has evolved away from buying branded products that can be 50% more expensive.
Procter & Gamble(PG-N)
December 19, 2018
They try to manage their P&L well to earn a 7-9% earnings growth rate and the yields have competed well against bonds. He is hesitant on this space, because society has evolved away from buying branded products that can be 50% more expensive.
Gordon Reid
President, GoodReid Investment Counsel
Price
$91.760
Owned
No
COMMENT
COMMENT
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
CVS Health Corp(CVS-N)
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
Gordon Reid
President, GoodReid Investment Counsel
Price
$68.590
Owned
Yes
COMMENT
COMMENT
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
Bank of America(BAC-N)
December 19, 2018
CVS or BAC? He owns both and struggles to pick one over the other. Building a portfolio with different balances makes sense. CVS is a little out of favour as it is being "Amazoned". However, they have 11,000 locations in the US and have set up mini-health clinics with nurses on staff -- a good differentiation. BAC has corrected and is now trading at recessionary levels (below book value) -- extreme levels not seen since 2008 and great value.
Gordon Reid
President, GoodReid Investment Counsel
Price
$24.180
Owned
Yes
DON'T BUY
DON'T BUY
December 19, 2018
It is hard to not be excited about their new technology in payment systems. His concern is paying 9 times revenue -- hugely expensive, he thinks. Maybe it stands the test of time, but he will pass at this level.
Square Inc(SQ-N)
December 19, 2018
It is hard to not be excited about their new technology in payment systems. His concern is paying 9 times revenue -- hugely expensive, he thinks. Maybe it stands the test of time, but he will pass at this level.
Gordon Reid
President, GoodReid Investment Counsel
Price
$59.030
Owned
No
DON'T BUY
DON'T BUY
December 19, 2018
They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.
Pfizer Inc(PFE-N)
December 19, 2018
They make their money by constantly cost cutting. When their drugs go off-patent then they need to find another to replace it. It is a leaky-boat story. When you look at the cost multiples, which he thinks are expensive, he would pass on this. He would consider bio-pharma instead.
Gordon Reid
President, GoodReid Investment Counsel
Price
$41.970
Owned
No